Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Fluticasone furoate/umeclidinium bromide/vilanterol dry powder inhaler (Trelegy Ellipta®) is a fixed-dose triple combination of a corticosteroid (ICS), a long-acting anti-muscarinic (LAMA) and a long-acting beta-agonist (LABA) for relief of symptoms in adults with chronic obstructive pulmonary disease.
This review is older than 3 years and has been archived. To request a copy, contact nuth.nyrdtc.rxsupp@nhs.net.